Zoetis Inc. (NYSE:ZTS) Shares Sold by Fundsmith LLP

Fundsmith LLP lessened its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 1.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 227,329 shares of the company's stock after selling 3,397 shares during the quarter. Fundsmith LLP owned 0.05% of Zoetis worth $37,039,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Callahan Advisors LLC increased its holdings in Zoetis by 90.4% during the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock valued at $2,135,000 after acquiring an additional 6,221 shares in the last quarter. CIBC Asset Management Inc increased its holdings in Zoetis by 24.1% during the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock valued at $38,617,000 after acquiring an additional 46,050 shares in the last quarter. Schroder Investment Management Group increased its holdings in Zoetis by 2.6% during the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock valued at $40,036,000 after acquiring an additional 6,169 shares in the last quarter. PFW Advisors LLC purchased a new position in Zoetis during the 4th quarter valued at about $1,764,000. Finally, Vanguard Group Inc. increased its holdings in Zoetis by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock valued at $6,739,905,000 after acquiring an additional 120,158 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares of the company's stock, valued at $2,757,196.26. The trade was a 1.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock valued at $312,254 over the last ninety days. Corporate insiders own 0.18% of the company's stock.

Zoetis Trading Down 1.1%

Zoetis stock traded down $1.73 during trading on Friday, reaching $159.96. The company had a trading volume of 4,243,109 shares, compared to its average volume of 2,492,973. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The stock's 50 day moving average price is $157.27 and its two-hundred day moving average price is $165.95. The firm has a market capitalization of $71.37 billion, a price-to-earnings ratio of 29.24, a PEG ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The firm had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Zoetis's revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.38 earnings per share. As a group, equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ZTS has been the subject of several recent research reports. Barclays raised their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Stifel Nicolaus lowered their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a report on Monday, April 14th. UBS Group lowered their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday. Morgan Stanley lowered their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Finally, StockNews.com upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $212.13.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.